Get the Stockscreener App
17.19
0.92%
-0.16
Omeros Corp stock is traded at $17.19, with a volume of 3.67M.
It is down -0.92% in the last 24 hours and up +63.71% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$17.35
Open:
$17.35
24h Volume:
3.67M
Relative Volume:
1.74
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$84.01M
P/E Ratio:
20.08
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
+29.74%
1M Performance:
+63.71%
6M Performance:
+47.05%
1Y Performance:
+317.23%
1-Day Range:
$16.54
$17.61
1-Week Range:
$13.00
$18.14
52-Week Range:
$3.94
$18.14
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
17.19 | 992.27M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far - Yahoo Finance
What is HC Wainwright's Forecast for Omeros FY2029 Earnings? - MarketBeat
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
OMER SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
OMEROS CORP SEC Filing (Aug 13, 2026) - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com
Biotech Stocks To ConsiderAugust 13th - MarketBeat
Omeros Sees Unusually Large Options Volume (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Sets New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
Omeros Corp (OMER) Shares Surge 29% on Q2 Beat; Price-to-Sales V - GuruFocus
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday - benzinga.com
Why is Omeros stock surging today? By Investing.com - Investing.com South Africa
Omeros Corp (OMER) Shares Surge 15% on Q2 Boost; Price-to-Sales Valuation Raises Growth Expectations - GuruFocus
Why Omeros Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Omeros Corp (OMER) Posts $28.5M Net Sales for YARTEMLEA's Debut Quarter Amid Valuation Concerns - GuruFocus
Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise - RTTNews
Omeros Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Omeros Q2 Earnings Call Highlights - MarketBeat
Omeros Q2 Results: Adj. EPS $0.02 beats $(0.27) estimate - scanx.trade
Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $0.29 EPS - MarketBeat
Earnings call transcript: Omeros Q2 2026 beats estimates, shares jump 20% - Investing.com
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
OMER Stock Soars 24% After-Hours On YARTEMLEA Sales Momentum, Debt Reduction And Share Buybacks - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Omeros earnings beat by $0.27, revenue topped estimates - Investing.com
What's going on in today's after hours session - ChartMill
Does Omeros Corp (OMER) Justify Its Low GF Score of 26/100 After Reporting $32.2 Million in Q2 Revenue? - GuruFocus
OMEROS ($OMER) Releases Q2 2026 Earnings, Stock Rises - quiverquant.com
Q2 2026 Omeros Corporation Earnings Call Transcript - GuruFocus
Omeros surges 13% on strong earnings and revenue beat By Investing.com - Investing.com India
Omeros surges 13% on strong earnings and revenue beat - Investing.com
Omeros Q2 2026 Earnings: YARTEMLEA Drives Operating Break-Even - tradingkey.com
Omeros: Q2 Earnings Snapshot - Yahoo Finance
Omeros Corporation (NASDAQ: OMER) turns profitable as YARTEMLEA sales ramp - Stock Titan
Omeros Corporation Reports Second Quarter 2026 Financial Results - Yahoo Finance
Omeros Corp (OMER) Q2 Earnings Preview: High Price-to-Sales Refl - GuruFocus
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 - Yahoo Finance
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
OMER|Omeros Corp|Price:13.250|Chg%:+0.100 - tradingkey.com
Omeros (OMER) to Announce Quarterly Earnings on Thursday - MarketBeat
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
OMER Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug - Yahoo Finance
Omeros (OMER) Gains CMS NTAP Approval for Yartemlea, But Valuati - GuruFocus
Medicare Hospitals Can Get Up to $287,079 to Treat a Transplant Complication - Stock Titan
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® - BioSpace
BlackRock (OMER) discloses 5.96M Omeros Corp shares in amended 13G filing - Stock Titan
H.C. Wainwright reiterates Omeros stock rating on rival trial miss By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Omeros stock rating on rival trial miss - Investing.com
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):